Zynex Announces Efforts to Address the Opioid Crisis

             Zynex Announces Efforts to Address the Opioid Crisis

PR Newswire

LONE TREE, Colo., Sept. 6, 2017

LONE TREE, Colo., Sept. 6, 2017 /PRNewswire/ -- Zynex, Inc. (OTCQB: ZYXI), an
innovative medical technology company specializing in the manufacture and sale
of non-invasive medical devices for pain management, stroke rehabilitation,
cardiac monitoring and neurological diagnostics, today announced an effort to
address the nationwide opioid crisis.

Zynex

Last month, the President declared the opioid epidemic a national emergency.
Patients suffering with chronic or debilitation pain are often prescribed
opioids as a first line of defense for their pain and the consequences of this
are devastating:

  o Death rates due to opioid abuse have increased substantially, with nearly
    100 Americans dying each day.
  o More people in the US die from drug overdoses than car accidents and
    nearly 2/3 of these were tied to opioid use.
  o The US labor force is feeling the impact as well. Almost 50% of the
    prime-age male labor force are on daily doses of pain medication while at
    work, negatively impacting worker productivity and increasing the amount
    companies spend on healthcare. 
  o Many applying for jobs are unable to pass drug tests, adding to the US
    labor shortage. In addition, workers are falling out of the job market due
    to seeking treatment for opioid abuse.
  o Opioid abuse has become a $80 billion problem in the US, and this is not
    isolated to any particular population. This crisis affects men as well as
    women, of all races, across all socio-economic levels.

Zynex's Founder and CEO, Thomas Sandgaard commented: "We strongly believe
Zynex's prescription-strength e-stim solution, hot/cold therapy, and spinal
bracing lines should be used as the first line of defense rather than
medication with so many negative side effects. We know that patients are less
likely to start down the path toward reliance on opioids when drug-free
options are available to them.  Our line of drug-free products can be
prescribed by health care practitioners through our exclusive EZ-Prescribe
program. This program makes prescribing our products as easy as prescribing
oral medications and is available to any practitioner nationwide. Our NexWave
device provides prescription strength pain relief without side effects.

"We are focused on increasing access to our drug-free solutions by expanding
our sales force presence and increasing awareness of our EZ-Prescribe program
to practitioners nationwide, including rural areas. We will be launching more
initiatives to raise awareness about our solutions and increase prescription
access to our products."

About Zynex 
Zynex, founded in 1996, markets and sells its own design of electrotherapy
medical devices used for pain management and rehabilitation; and the company's
proprietary NeuroMove device designed to help recovery of stroke and spinal
cord injury patients. Zynex is also developing a new blood volume monitor for
use in hospitals and surgery centers.  For additional information, please
visit: Zynex.com.

Safe Harbor Statement 
Certain statements in this release are "forward-looking" and as such are
subject to numerous risks and uncertainties. Actual results may vary
significantly from the results expressed or implied in such statements.
Factors that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the need to obtain
additional capital or augment our liquidity in order to continue our business,
the success of our international expansion efforts, our ability to engage
additional sales representatives and their success, the need to obtain FDA
clearance and CE marking of new products, the acceptance of new products as
well as existing products by doctors and hospitals, larger competitors with
greater financial resources, the need to keep pace with technological changes,
our dependence on the reimbursement from insurance companies for products sold
or rented to our customers, acceptance of our products by health insurance
providers, our dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales strategy including
a strong direct sales force, the uncertain outcome of pending material
litigation, our ability to up-list to a larger exchange and other risks
described in our filings with the Securities and Exchange Commission including
the "Risk Factors" section of our Annual Report on Form 10-K for the year
ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases
and the Company's website.

Contact: Zynex, Inc.  (303) 703-4906 
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

 

View original content with
multimedia:http://www.prnewswire.com/news-releases/zynex-announces-efforts-to-address-the-opioid-crisis-300514445.html

SOURCE Zynex

Website: http://Zynex.com
Press spacebar to pause and continue. Press esc to stop.